JP2022522405A5 - - Google Patents

Info

Publication number
JP2022522405A5
JP2022522405A5 JP2021543386A JP2021543386A JP2022522405A5 JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5 JP 2021543386 A JP2021543386 A JP 2021543386A JP 2021543386 A JP2021543386 A JP 2021543386A JP 2022522405 A5 JP2022522405 A5 JP 2022522405A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
mhc class
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522405A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021138 external-priority patent/WO2020181062A1/en
Publication of JP2022522405A publication Critical patent/JP2022522405A/ja
Publication of JP2022522405A5 publication Critical patent/JP2022522405A5/ja
Pending legal-status Critical Current

Links

JP2021543386A 2019-03-06 2020-03-05 T細胞調節多量体ポリペプチド及びその使用方法 Pending JP2022522405A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814721P 2019-03-06 2019-03-06
US62/814,721 2019-03-06
PCT/US2020/021138 WO2020181062A1 (en) 2019-03-06 2020-03-05 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2022522405A JP2022522405A (ja) 2022-04-19
JP2022522405A5 true JP2022522405A5 (cg-RX-API-DMAC7.html) 2023-03-09

Family

ID=72338760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543386A Pending JP2022522405A (ja) 2019-03-06 2020-03-05 T細胞調節多量体ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (2) US20220105162A1 (cg-RX-API-DMAC7.html)
EP (1) EP3935080A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022522405A (cg-RX-API-DMAC7.html)
WO (1) WO2020181062A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
CA3061614A1 (en) 2017-04-28 2018-11-01 The Regents Of The University Of Colorado, A Body Corporate Methods of treating rheumatoid arthritis using rna-guided genome editing of hla gene
WO2019051127A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance
JP2024517658A (ja) * 2021-04-21 2024-04-23 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節ポリペプチド及びその使用方法
WO2022226037A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
WO2022226073A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides and methods of use thereof
MX2023013438A (es) 2021-05-10 2024-02-29 Univ Colorado Regents Métodos de diseño de hla y composiciones para el tratamiento de la autoinmunidad.
US20240327492A1 (en) * 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
WO2025111562A1 (en) * 2023-11-22 2025-05-30 Cue Biopharma, Inc. Mhc class ii protein complexes

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
DK0776339T4 (da) * 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス, インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2593551B1 (en) * 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
JP6652932B2 (ja) * 2014-06-18 2020-02-26 アルバート アインシュタイン カレッジ オブ メディシン synTacポリペプチド及びその使用
ES3055030T3 (en) * 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
IL262606B2 (en) * 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
US20180127481A1 (en) * 2016-11-09 2018-05-10 Uti Limited Partnership RECOMBINANT pMHC CLASS II MOLECULES
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법

Similar Documents

Publication Publication Date Title
JP2022522404A5 (cg-RX-API-DMAC7.html)
JP2021500855A5 (cg-RX-API-DMAC7.html)
Todd et al. A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus
Choo The HLA system: genetics, immunology, clinical testing, and clinical implications
Todd et al. A molecular basis for MHC class II—associated autoimmunity
Kelly et al. A new human HLA class II-related locus, DM
Spies et al. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer
Flajnik et al. Evolution of the major histocompatibility complex: molecular cloning of major histocompatibility complex class I from the amphibian Xenopus.
AU2025202532A9 (en) HLA Class II-restricted T cell receptors against mutated RAS
Czaja Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis
JP2022536581A5 (cg-RX-API-DMAC7.html)
JP2022534846A5 (cg-RX-API-DMAC7.html)
JP2022515330A5 (cg-RX-API-DMAC7.html)
JP2019512222A5 (cg-RX-API-DMAC7.html)
Gregersen HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease
JP2023541366A5 (cg-RX-API-DMAC7.html)
Parham et al. HLA-A, B, C: Patterns of polymorphism in peptide-binding proteins
Thorsby et al. Role of HLA genes in predisposition to develop insulin-dependent diabetes mellitus
Cook et al. Structural Studies on the Murine Ia Alloantigens: IV. NH2-Terminal Sequence Analysis of Allelic Products of the IA and IE/C Subregions
EP0286447B1 (en) Method and agents relating to prophylactic treatment of autoimmune diseases
Hurley et al. Polymorphism of the HLA-DR1 haplotype in American blacks. Identification of a DR1 beta-chain determinant recognized in the mixed lymphocyte reaction.
Ababou et al. Evidence for the expression of three different BoLA-class II molecules on the bovine BL-3 cell line: determination of a non-DR non-DQ gene product
Nepom MHC genes in HLA-associated disease
Weyand et al. Mapping of allospecific T-cell recognition sites encoded by the HLA-DR4 β1-chain
Deschamps et al. The role of genetic predisposition to type I (insulin-dependent) diabetes mellitus